Although there are no FDA-approved treatments specifically indicated for low-grade serous ovarian cancer, therapeutic options for these patients are rapidly expanding, with promising new approaches progressing through clinical development.
Expert oncologist David M. O’Malley, MD, reviews data from the RAMP 201 study utilizing avutometinib +/- defactinib in patients with recurrent low grade serous ovarian cancer and considers how this combination approach may impact the treatment landscape.
Data Build on Breakthrough Therapy Designation of the Combination of Avutometinib and Defactinib in Low-Grade Serous Ovarian Cancer
Clinically Meaningful Response Rates and Manageable Safety and. | May 25, 2023
New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society. | May 9, 2023